SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Bankr is an advanced AI agent focused on simplifying the process of buying and selling digital assets. Bankr was the first AI agent on Farcaster to help you quickly buy all your favorites coins directly in the social. BankrCoin is the official coin of the agent and was deployed by Bankr itself directly in the Farcaster social feed. Fees from swaps go to support BankrCoin. Bankr is available on Farcaster and will soon be launching a private terminal, token recs, and limit orders on Base.

BankrCoin

BankrCoin is attracting significant attention as investors speculate on its AI-driven infrastructure and potential for long-term utility growth within the Base ecosystem. The community remains focused on accumulation and holding, viewing recent market dips as entry points for a project they believe is heavily undervalued relative to its sector peers.

Reactive Network is the first parallelized interoperability execution layer, utilising a new form of smart contract we call reactive smart contracts.   Reactive smart contracts are able to react to on-chain events autonomously and execute their own user defined logic to initiate new transactions. This allows a virtually limitless number of use cases to achieve fully decentralized on-chain automation.

Reactive Network

Reactive Network is gaining significant community traction as investors anticipate major exchange listings and positive momentum from Ethereum's evolving technical landscape. The community is actively discussing the platform's potential for cross-chain automation and is focused on holding through price volatility as they wait for increased market exposure.

Ventas, Inc. engages in the acquisition and ownership of seniors housing and healthcare properties. It operates through the following segments: Senior Housing Operating Portfolio (SHOP), Outpatient Medical and Research Portfolio (OM&R), and Triple-net Leased Properties (NNN). The SHOP segment is involved in owning and investing in senior housing communities throughout the United States and Canada. The OM&R segment refers to acquiring, owning, development, leasing and managing outpatient medical buildings and research centers throughout the United States. The NNN segment focuses on investing and owning senior housing communities, skilled nursing facilities, long-term acute care facilities, freestanding inpatient rehabilitation facilities, and other healthcare facilities throughout the United States and the United Kingdom. The company was founded in 1983 and is headquartered in Chicago, IL.

Ventas Inc

Ventas is drawing attention as investors highlight its resilient senior housing portfolio and demographic tailwinds, while the community actively debates its technical breakout potential toward higher price levels. Sentiment remains split between those focused on its defensive yield and long-term recovery story versus those concerned about macro headwinds and interest rate sensitivity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is currently experiencing high volatility as investors navigate aggressive swings driven by a mix of geopolitical tensions, central bank policy concerns, and sector-specific earnings. Community sentiment is deeply polarized, with active debates centered on whether the current semiconductor rally is a sustainable AI-driven shift or a speculative bubble vulnerable to a sharp correction.

Microchip Technology, Inc. engages in the provision of semiconductor products. It operates through the Semiconductor Products and Technology Licensing segments. The Semiconductor Products segment is involved in designing, developing, manufacturing, and marketing microcontrollers, development tools and analog, interface, mixed signal, connectivity devices, and timing products. The Technology Licensing segment offers license fees and royalties associated with technology licenses for the use of SuperFlash embedded flash and Smartbits one-time programmable technologies. The company was founded on February 14, 1989 and is headquartered in Chandler, AZ.

Microchip Technology, Inc.

Microchip Technology is trending as the community debates its recovery potential and valuation amid a challenging semiconductor cycle. Investors are closely monitoring its operational rebound following a recent cyberattack while weighing its long-term positioning in industrial, automotive, and data center markets.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is trending as investors weigh the stock's recent volatility against its aggressive expansion into crypto trading and AI-integrated wealth management tools. The community remains divided, with many traders discussing the firm's system reliability and restrictions, while others view the pullback as a buying opportunity given the company's strong long-term client asset growth.

Bitwise XRP ETF - Common Shares Of Beneficial Interest

Bitwise XRP ETF

Community sentiment for XRP remains heavily influenced by the anticipated passage of the CLARITY Act, which investors believe will provide regulatory certainty and facilitate broader institutional integration for the token. Discussions are currently polarized between bulls who are actively accumulating on dips in expectation of a major price rally and skeptics who remain cautious due to historical price volatility and market structure concerns.

American Eagle Outfitters, Inc. is a multi-brand specialty retailer, which offers an assortment of apparel and accessories for men and women under the American Eagle Outfitters brand, and intimates, apparel and personal care products for women under the Aerie brand. The firm operates stores in the United States, Canada, Mexico, Hong Kong, China and the United Kingdom. It also acquired two emerging brands to complement its existing brands, Tailgate, a vintage sports-inspired apparel brand, and Todd Snyder New York, a premium menswear brand. The company was founded in 1977 and is headquartered in Pittsburgh, PA.

American Eagle Outfitters Inc.

American Eagle Outfitters, Inc.

American Eagle Outfitters is experiencing heightened market activity driven by a potent mix of strong quarterly earnings, upbeat forward guidance, and highly effective celebrity-led marketing campaigns featuring Sydney Sweeney. While bullish investors are encouraged by the stock's momentum and significant short interest fueling squeeze potential, some community members express caution regarding its sustainability amidst broader retail sector pressures and recent rapid price appreciation.

Intuit, Inc. engages in the provision of business and financial management solutions. It operates through the following segments: Small Business and Self-Employed, Consumer, Credit Karma, and ProTax. The Small Business and Self-Employed segment offers QuickBooks financial and business management online services and desktop software, payroll solutions, payment processing solutions, and financing for small businesses. The Consumer segment includes do-it-yourself and assisted TurboTax income tax preparation products and services. The Credit Karma segment serves consumers with a personal finance platform that provides personalized recommendations of credit cards, home, auto and personal loans, and insurance products, and online savings and checking accounts. The ProTax segment refers to the professional accountants in the U.S. and Canada, who are essential to both small business success and tax preparation and filing. The company was founded by Scott D. Cook and Thomas A. Proulx in March 1983 and is headquartered in Mountain View, CA.

Intuit Inc

Intuit is trending as traders weigh an AI-driven partnership with Anthropic against broader sector fears that LLM-based competitors could disrupt its financial software dominance. The community remains divided, with many aggressively buying the dip on the belief that Intuit's entrenched user base and essential tax workflows provide a durable moat against AI-induced margin compression.

Baby Doge Coin is a meme cryptocurrency designed to be deflationary and more scarce over time. All holders of Baby Doge will earn more baby doge that is automatically sent to your wallet by simply holding Baby Doge coins in your wallet. Watch the amount of baby doge grow in your wallet as baby doge coin holders automatically receive a 5% fee from every on chain transaction that happens on the Baby Doge ecosystem. The community receives more baby doge coins from the fees generated each transaction.

Baby Doge Coin

Baby Doge Coin is trending as the community rallies around strong momentum and speculation regarding potential major exchange listings. Investors are actively debating the token's long-term utility versus market manipulation, with many choosing to accumulate during price swings while aiming for significant future gains.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer

Atossa Therapeutics to Host Virtual KOL Event Featuring Dr. Laura Esserman to Discuss Development of (Z)-Endoxifen in ER-Positive Breast Cancer Atossa Therapeutics to Host Virtual KOL Event Featuring...

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update PR...

<ul class="summary-bullets"><li>The RPD designation is given to therapies targeting serious or life-threatening conditions that primarily affect children.</li><li>(Z)-endoxifen already has an RPD designation for the treatment of Duchenne muscular dystrophy.</li><li>Atossa is currently evaluating the potential applications of (Z)-endoxifen in oncology and rare diseases</li></ul>Atossa Therapeutics (ATOS) was on investors’ radar on Monday, with the stock gaining more than 8%, after the U.S. Food and Drug Administration granted Rare Pediatric Disease designation to its drug for the treatment of McCune-Albright Syndrome in females.The RPD designation is given to therapies targeting serious or life-threatening conditions that primarily affect children. If approved through a New Drug Application (NDA) or a Biologics License Application (BLA), drugs with RPD designation may qualify for a Priority Review Voucher (PRV), which provides an expedited review process.“McCune-Albright Syndrome (MAS) is a rare and serious pediatric disorder with significant unmet medical need, particularly in young girls affected by hormone dysregulation and early puberty. We believe (Z)-endoxifen has the potential to address key disease drivers and improve outcomes for these patients, while also creating potential non-dilutive value through the Rare Pediatric Disease program,” said CEO Steven Quay.MAS is a rare disorder that can cause early puberty, abnormal bone growth, and endocrine issues in young patients.<h2 class="st-heading-2">Treatment Of DMD</h2>(Z)-endoxifen already has an RPD designation. In December 2025, the FDA granted RPD designation to the drug for the treatment of Duchenne muscular dystrophy (DMD), a severe, genetic muscle disorder that primarily affects young boys. Atossa added that over the past 18 to 24 months, publicly reported PRV sales have ranged between about $100 million and $205 million.Atossa is evaluating the potential applications of (Z)-endoxifen in oncology and rare diseases, though it has not yet been approved for any indication.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for <a href="https://stocktwits.com/symbol/ATOS">ATOS</a> on Stocktwits turned ‘neutral’ from ‘bearish’ a day earlier.Given the importance of the news, one user expressed disappointment that the stock could not climb to $10. It is currently trading around $5.7.<stembedurl>https://stocktwits.com/todn/message/652163632</stembedurl>The stock has declined more than 40% so far this year.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/akan-stock-crashes-32-percent-fugazi-short-report/cZQMzHoReJN">AKAN Stock Crashes 32% – Why This Short Seller Sees ‘Zero Fundamental Value’ In Akanda’s Shares</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Atossa Therapeutics logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ATOS Stock Jumps 8% Today – An FDA Designation Draws Investor Cheer For Atossa Therapeutics

The U.S. Food and Drug Administration granted Rare Pediatric Disease designation to Atossa’s drug for the treatment of McCune-Albright Syndrome in females.

Equity

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome

Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for McCune-Albright Syndrome Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for...

<ul class="summary-bullets"><li>The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.&nbsp;</li><li>The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91.</li><li>Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer.</li></ul>Shares of Atossa Therapeutics (ATOS) slipped 4% after hours on Wednesday after the company said that it continues to align its resources towards potential commercialization of (Z)-endoxifen after it reported a wider full year loss.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.atossatherapeutics.com/2026-03-25-Atossa-Therapeutics-Reports-Fourth-Quarter-and-Year-End-2025-Financial-Results-and-Provides-a-Corporate-Update">said</a> that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer. The investigational therapy was granted Rare Pediatric Disease designation for the treatment of DMD in December and an Orphan Drug Designation in January.“We believe these FDA designations are important for future development as they both help to speed the FDA review process as well as provide potential financial benefits in the future," CEO Steven Quay said on Wednesday.Last month, Atossa said that the company will not proceed with advancing its drug in metastatic breast cancer due to the overall cost and timeline required to conduct later-stage studies in the indication. The company then said it will prioritize its resources on other oncology and rare disease areas with “higher potential returns on investments.”<h2 class="st-heading-2">Q4 Earnings</h2>The company said on Wednesday that its operating expenses rose in 2025 to $37.1 million, compared to $9.5 million in 2024, owing to a significant rise in research and development expenses for (Z)-endoxifen.The company reported net loss per share of $4.04 for 2025, compared to a loss of $3.04 in 2024, and above an analyst estimate of a loss of $3.91. The company ended the year with cash and cash equivalents of $41.29 million, compared to $71.08 million as of 2024-end.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around ATOS stock stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<a href="https://stocktwits.com/symbol/ATOS">ATOS stock</a> has dropped 50% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/wkhs-stock-rallies-after-hours-on-unveiling-cheaper-electric-delivery-van/cZ3pPW4RIjI">WKHS Stock Rallies After Hours On Unveiling Cheaper Electric Delivery Van</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

ATOS Stock Drops After Hours On Earnings Miss — CEO Now Bets On New Uses For Its Experimental Cancer Drug

The company said that it is working to advance its experimental drug (Z)-endoxifen in certain rare disease indications such as Duchenne Muscular Dystrophy (DMD) and McCune-Albright Syndrome (MAS) in addition to breast cancer.

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update

Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides a Corporate Update Atossa Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and...

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives

Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two Experienced Biopharma Executives Atossa Therapeutics Strengthens Clinical Leadership Team with the Addition of Two...

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference

Atossa Therapeutics Presents Clinical Trial Update Highlighting (Z)-Endoxifen Research at the 2026 MDA Clinical & Scientific Conference Atossa Therapeutics Presents Clinical Trial Update Highlighting...

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program Atossa Therapeutics Maintains Strong...

Atossa Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company was founded by Steven C. Quay and Shu Chih Chen in December 2008 and is headquartered in Seattle, WA.

ATOS
Atossa Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ATOS News

ATOSAtossa Therapeutics Inc